BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Aegera Therapeutics Inc. 

810 chemin du Golf

Ile des Soeurs (Montreal)  Quebec  H3E 1A8   Canada
Phone: 514-288-5532 Fax: 514-288-9280


SEARCH JOBS


Industry
Biotechnology






 Company News
Pharmascience Inc. Acquires Aegera Therapeutics; Aegera's Employees to Retain Their Jobs 5/27/2011 6:35:25 AM    More...
Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma 1/26/2010 9:45:13 AM    More...
Human Genome Sciences, Inc. (HGSI) and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors 11/23/2009 10:04:55 AM    More...
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 11/19/2009 8:52:38 AM    More...
Aegera Therapeutics Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety Profile 11/16/2009 8:52:53 AM    More...
Aegera Therapeutics Closes CDN $7 Million Financing 9/23/2009 10:57:37 AM    More...
Aegera Therapeutics Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 5/6/2009 11:32:55 AM    More...
Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer 1/8/2009 10:33:48 AM    More...
Aegera Therapeutics Phase 1/2 Clinical Trial Results Selected for Oral Presentation at 2008 American Society of Hematology Annual Meeting 11/25/2008 9:29:39 AM    More...
Neurologix, Inc. Licenses Exclusive Rights to Key Gene from Aegera Therapeutics for Use as a Potential Gene Therapy for Huntington's Disease 9/3/2008 6:06:48 AM    More...
1234

//-->